Law360, New York (March 29, 2012, 4:14 PM EDT) -- A federal judge on Wednesday rejected AstraZeneca PLC’s attempt to block generic versions of its antipsychotic drug Seroquel from going to market, but also criticized the U.S. Food and Drug Administration for dragging out the court's review of the matter.
In refusing to grant a restraining order, U.S. District Judge Beryl A. Howell said she was deferring to the expertise of FDA officials who determined AstraZeneca was no longer entitled to exclusive rights over Seroquel.
“The court will defer to this conclusion so long as it...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.